证券代码：605507 证券简称：国邦医药 公告编号：2025-028 三、其他情况说明 公司将按照《上海证券交易所股票上市规则》及相关法律法规的要求，密切 关注投资基金的后续进展情况，及时履行信息披露义务，敬请广大投资者注意投 资风险。 特此公告。 国邦医药集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资概述 为进一步推动国邦医药集团股份有限公司（以下简称"公司"）的战略及投 资布局，借助专业投资机构和高校科技成果的资源优势，进一步扩大公司在科技 领域投资。公司全资子公司国邦医药（杭州）股权投资有限公司（以下简称"国 邦投资"）作为有限合伙人以自有资金 1,000 万元人民币参与设立股权投资基金， 重点投资符合国家战略性新兴产业、未来产业发展方向领域的公司。具体内容详 见公司于 2025 年 4 月 22 日在上海证券交易所网站（www.sse.com.cn）披露的《国 邦医药关于全资子公司参与设立股权投资基金的公告》（公告编号：2025-021）。 二、对外投资进展 近日，公司收到杭州启真开物 ...

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, and others [3]. Core Insights - The pharmaceutical sector has outperformed the market, with a focus on the potential of innovative drugs and the CD73 target in cancer immunotherapy [4][5]. - The report highlights the promising clinical progress of CD73 inhibitors, with several products in various stages of clinical trials [21][25]. Summary by Sections Industry Investment Rating - The report provides a list of recommended companies with "Buy" and "Hold" ratings, indicating strong investment potential in the pharmaceutical sector [3]. Industry Performance - The pharmaceutical sector rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points, with innovative drugs and vaccines leading the performance [5][32]. Company Dynamics - Companies such as Lepu Medical and Sunshine Nuohua have made significant announcements regarding new product approvals and clinical trial progress, indicating a robust pipeline and growth potential [33][34]. Industry Trends - The report discusses the increasing focus on innovative drugs and the impact of regulatory changes on the pharmaceutical landscape, suggesting a shift towards high-efficiency business models in the industry [31][40].

国浩律师（杭州）事务所 关 于 国邦医药集团股份有限公司 差异化分红事项 之 专项法律意见书 关 于 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二〇二五年五月 国浩律师（杭州）事务所 法律意见书 国浩律师（杭州）事务所 国邦医药集团股份有限公司 差异化分红事项 之 专项法律意见书 致：国邦医药集团股份有限公司 国浩律师（杭州）事务所接受国邦医药集团股份有限公司（以下简称"国邦 医药"或"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证 ...

每股分配比例 A 股每股现金红利0.60583元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/12 | － | 2025/6/13 | 2025/6/13 | 差异化分红送转： 是 一、通过分配方案的股东大会届次和日期 证券代码：605507 证券简称：国邦医药 公告编号：2025-027 国邦医药集团股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次利润分配方案经公司2025 年 4 月 25 日的2024年年度股东大会审议通过。 二、分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《上海证券交易所上市公司自律监管指引第 7 号—回购股份》的规定， 公司存放于回购 ...

Investment Rating - The report maintains a "Recommendation" rating for the animal health industry, expecting it to outperform the benchmark index by over 5% in the next 3-6 months [79]. Core Insights - The report highlights significant growth in vaccine approvals for circular, pseudorabies, and diarrhea vaccines, with notable year-on-year increases [7][8]. - The animal drug raw material market shows a continued strong performance in macrolide products, with price indices reflecting a structural differentiation among various products [52][53]. - The overall demand for animal health products is expected to recover, driven by improved profitability in the breeding sector and the introduction of new products [68][69]. Summary by Sections Vaccine Approvals - In April, major vaccine varieties for pigs showed substantial year-on-year growth, with circular vaccine up by 71.2%, pseudorabies vaccine by 73.3%, and diarrhea vaccine by 220% [7][8]. - Cumulative data from January to April indicates most vaccine types experienced significant growth, particularly in pig vaccines, with circular vaccine up by 52.3% and pseudorabies vaccine by 48.2% [8][9]. Raw Material Prices - As of the end of April, the Veterinary Pharmaceutical Index (VPI) was 69.2, reflecting a 5.6% increase from the previous month and a 13.4% increase year-on-year [52][53]. - Prices for macrolide products such as Tylosin, Tylvalosin, and Tilmicosin have shown strong performance, with increases of 10.1%, 17.6%, and 15.4% respectively compared to the end of March [53][54]. Market Outlook - The report anticipates a stable upward trend in the demand for animal health products, supported by a robust breeding sector and ongoing product innovation [68][69]. - The competitive landscape is expected to lead to a dual recovery in performance and valuation for the sector, with a focus on larger companies that can leverage their financial strength and product diversity [69][70]. Investment Recommendations - The report suggests focusing on companies such as Reap Bio, Kexin Bio, and others, which are well-positioned to benefit from the anticipated market recovery [68][70].

证券代码：605507 证券简称：国邦医药 公告编号：2025-026 国邦医药集团股份有限公司 关于股份回购进展公告 二、回购股份的进展情况 根据《上市公司股份回购规则》及《上海证券交易所上市公司自律监管指引 第 7 号——回购股份》的相关规定，现将公司回购股份的进展情况公告如下： 截至 2025 年 5 月 31 日，公司通过集中竞价交易方式累计回购股份 5,375,274 股，已回购股份占公司总股本的比例为 0.96%，成交的最高价为 19.88 元/股，最低 价为 18.61 元/股，已支付的总金额为 102,600,172.21 元（不含交易费用）。 上述回购事项符合相关法律法规的规定及公司回购股份方案的要求。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/11 | | --- | --- | | 回购方案实施期限 | 2025/3/11~2026/3/10 | | 预计回购金额 | 1亿元~2亿元 | | | □减少注册资本 | | | √用于员工持股计划 ...

证券代码：605507 证券简称：国邦医药 公告编号：2025-026 根据《上市公司股份回购规则》及《上海证券交易所上市公司自律监管指引 第 7 号——回购股份》的相关规定，现将公司回购股份的进展情况公告如下： 截至 2025 年 5 月 31 日，公司通过集中竞价交易方式累计回购股份 5,375,274 股，已回购股份占公司总股本的比例为 0.96%，成交的最高价为 19.88 元/股，最低 价为 18.61 元/股，已支付的总金额为 102,600,172.21 元（不含交易费用）。 重要内容提示： | 回购方案首次披露日 | 2025/3/11 | | --- | --- | | 回购方案实施期限 | 2025/3/11~2026/3/10 | | 预计回购金额 | 1亿元~2亿元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 5,375,274股 | | 累计已回购股数占总股本比例 | 0.96% | | 累计已回购金额 | 102,600,172.21元 | | 实际回购价格 ...

Core Viewpoint - The company has adjusted its profit distribution plan for the year 2024, increasing the cash dividend per share from 0.60000 yuan (including tax) to 0.60583 yuan (including tax) due to changes in the total share capital resulting from share buybacks [1][3]. Summary by Sections Adjusted Profit Distribution Plan - The cash dividend per share has been revised to 0.60583 yuan (including tax) from the previously announced 0.60000 yuan (including tax) [1][3]. - The adjustment is a result of the company's share buyback activities, which altered the total number of shares eligible for profit distribution while keeping the total distribution amount unchanged [1][3]. Previous Profit Distribution Plan - The initial profit distribution plan was approved on March 27, 2025, and April 25, 2025, with a total cash dividend of 335,019,120 yuan (including tax) based on a total share capital of 558,823,500 shares, excluding 458,300 shares held in the buyback account [1][2]. - The plan was based on the total share capital minus the shares in the buyback account, resulting in a base of 558,365,200 shares for the distribution [1][2]. Calculation of Adjusted Dividend - The actual number of shares eligible for distribution is calculated as 558,823,500 shares minus 5,833,574 shares in the buyback account, resulting in 552,989,926 shares [3]. - The adjusted cash dividend per share is calculated by dividing the total cash dividend amount (335,019,120 yuan) by the number of shares eligible for distribution (552,989,926), yielding approximately 0.60583 yuan per share [3]. - The total profit distribution amount remains approximately 335,017,886.87 yuan (including tax) after rounding [3]. Assurance of Distribution Implementation - The company will not engage in any actions that could alter the total share capital or the number of shares in the buyback account from the date of submitting the special application for differentiated rights distribution until the completion of the profit distribution [4].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配金额：每股派发现金红利由 0.60000 元（含税）调整为 0.60583 元（含税）。 本次调整原因：自 2024 年度利润分配方案披露之日起至本公告披露日， 国邦医药集团股份有限公司（以下简称"公司"）通过上海证券交易所交易系统 以集中竞价交易方式实施股份回购，公司享有利润分配权的总股本发生变动，按 照分配总额不变，相应调整每股分配比例的原则，对公司 2024 年度利润分配方 案的每股现金分红金额进行相应调整。 一、调整前利润分配方案 证券代码：605507 证券简称：国邦医药 公告编号：2025-025 国邦医药集团股份有限公司 关于调整 2024 年度利润分配方案每股分配金额的公告 公司分别于 2025 年 3 月 27 日、2025 年 4 月 25 日召开第二届董事会第十二 次会议及 2024 年年度股东大会，审议通过了《关于公司 2024 年度利润分配方案 的议案》。本次利润分配方案如下：公司拟以实施权益分派股权登记日登记的总 股本扣除公司回 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Views - The report highlights that the operating turning point for Guobang Pharmaceutical is evident, with the animal health business expected to contribute significantly to performance elasticity [5][13] - The pharmaceutical raw materials sector is maintaining a high level of prosperity due to upstream intermediate supply constraints and sustained post-pandemic demand [6][27] - The animal health raw materials sector is nearing the end of a market clearing phase, with prices for strong antibiotics showing a continuous recovery [7][42] Summary by Sections Guobang Pharmaceutical - Guobang Pharmaceutical has shown steady revenue growth, increasing from 4.206 billion in 2020 to 5.891 billion in 2024, with profits stabilizing around 800 million [13][14] - The gross margin for animal health raw materials has decreased significantly, reaching a historical low of 18.9% in 2024, while the gross margin for pharmaceutical raw materials has improved to 28.4% [17][19] - The company is experiencing a recovery in profitability, with gross margin, net margin, and ROE showing signs of improvement in 2024 [19][25] Pharmaceutical Raw Materials - The pharmaceutical raw materials segment, particularly macrolide antibiotics, is expected to maintain high profitability due to limited upstream supply and stable demand growth [6][27] - Key products include Azithromycin, Clarithromycin, and Roxithromycin, with the core raw material being thiocyanate erythromycin, which is crucial for production [27][30] Animal Health Raw Materials - The animal health raw materials market is stabilizing, with strong antibiotic prices recovering after a prolonged decline [7][42] - The market for strong antibiotics has shifted from over ten competitors to about three major players, with Guobang Pharmaceutical holding a significant market share [7][49] - The price of Florfenicol has dropped significantly from 500 RMB/kg in 2022 to around 180 RMB/kg in 2024, but is now showing signs of stabilization [7][50] Market Performance - In May, the pharmaceutical and biotechnology sector rose by 1.78%, outperforming the CSI 300 index by 1.96 percentage points, ranking first among 31 sub-industries [55][60] - The other biopharmaceutical sub-sector showed the highest growth, while the hospital sector experienced the largest decline [60][61]